Recent Company News

• 11:21 AM ET Jun 02, 2025
  

  Adlai Nortye downgraded to neutral from buy at HC Wainwright (timing uncertain) ($1.69, -0.14)

• 10:10 AM ET Apr 08, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (30 total)

• 04:33 PM ET Apr 09, 2024
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:30 AM ET Apr 09, 2024
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:08 AM ET Sep 04, 2024
  

  Adlai Nortye initiated buy at HC Wainwright

• 08:41 AM ET Aug 08, 2024
  

  Adlai Nortye reports H1 net income ($27.7M) vs year-ago ($78.6M)

• 09:08 PM ET May 23, 2024
  

  Adlai Nortye to present preliminary data of AN0025 in combination with definitive chemoradiotherapy in unresectable locally advanced or locally recurrent esophageal cancer at ASCO

• 08:10 AM ET May 22, 2024
  

  Adlai Nortye announces first patient dosed in randomized Phase II clinical trial of palupiprant (AN0025) for the treatment of locally advanced rectal cancer with radiation therapy